Core Insights - Candel Therapeutics (NASDAQ: CADL) shows promising results in immunotherapy for pancreatic cancer and is advancing late-stage studies in prostate cancer [1] Company Analysis - The company has demonstrated impressive clinical trial results, particularly in the area of immunotherapy for pancreatic cancer, which may present significant investment opportunities [1] - Late-stage studies in prostate cancer further enhance the company's potential for growth and success in the biotech sector [1] Industry Context - The biotech industry continues to evolve with advancements in immunotherapy, highlighting the importance of thorough analysis and understanding of clinical trials for potential investors [1]